Combination Chemotherapy for Lung Cancer
Author Information
Author(s): Fujita A, Ohkubo T, Hoshino H, Takabatake H, Tagaki S, Sekine K, Abe S
Primary Institution: Minami-ichijo Hospital
Hypothesis
Can a combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support improve treatment outcomes for patients with advanced non-small-cell lung cancer?
Conclusion
The combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support was highly effective for treating stage IIIB or IV non-small-cell lung cancer.
Supporting Evidence
- The overall response rate was 67.3%.
- The median survival time was 540 days.
- Grade 3 or 4 neutropenia occurred in 63.3% of patients.
- 33 patients achieved a partial response.
Takeaway
This study tested a new mix of medicines to help people with a serious type of lung cancer, and it worked well for many of them.
Methodology
Patients with advanced non-small-cell lung cancer were treated with a combination of cisplatin, ifosfamide, and irinotecan, and their responses were monitored.
Potential Biases
Potential selection bias due to strict eligibility criteria.
Limitations
The study had a small sample size and was limited to specific patient criteria.
Participant Demographics
31 men and 19 women, median age 57 years (range 38–71).
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 57.4–77.2%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website